Drug Logix India Private Limited provides comprehensive, science-driven Potential Nitrosamine Impurities Assessment Services for Active Pharmaceutical Ingredients (APIs), drug products, intermediates, starting materials, excipients and manufacturing processes.
Nitrosamine impurities are a significant pharmaceutical quality and patient-safety concern due to their potential genotoxic and carcinogenic properties. Regulatory authorities worldwide expect manufacturers and Marketing Authorization Holders (MAHs) to conduct systematic risk evaluations and implement appropriate control strategies where a potential risk is identified.
We support clients through a structured, scientifically justified and regulatory-oriented assessment, covering the complete manufacturing lifecycle — from raw materials and starting materials through intermediates, APIs, drug products and associated manufacturing processes.
Request a Nitrosamine AssessmentIdentification of potential nitrosamine impurities associated with APIs and drug products, including scientific evaluation of potential nitrosamine structures.
Evaluation of nitrosamine formation pathways and mechanisms based on chemical structure and the manufacturing process.
Assessment of nitrosatable amines, nitrite sources, nitrate sources and other potential precursors across the process.
Evaluation of raw materials, starting materials, intermediates, reagents, solvents, catalysts and processing aids for potential nitrosamine risks.
Assessment of process conditions that may promote nitrosamine formation — pH, temperature, reaction conditions and processing steps.
Evaluation of potential risks arising from degradation pathways and drug-product manufacturing or storage conditions.
Review of supplier- and material-related risks including potential contamination, carryover and cross-contamination, where applicable.
Evaluation of existing analytical controls and specifications, and identification of additional testing requirements where scientifically justified.
Development and recommendation of suitable risk-mitigation and control strategies for identified nitrosamine risks.
This approach enables clients to establish a clear scientific rationale for determining whether potential nitrosamine impurities are reasonably likely to form, whether additional analytical evaluation is warranted, and what appropriate mitigation measures should be considered.
Our assessment can be performed based on relevant technical and manufacturing information, including:
Depending on the project scope, Drug Logix can provide:
Drug Logix prepares scientifically justified and audit-ready technical assessment reports that can support regulatory submissions, customer audits, internal quality assessments and responses to regulatory queries. Our approach is aligned with the principles and expectations established through applicable regulatory guidance, including ICH M7 principles for assessment and control of DNA-reactive impurities, together with relevant regulatory expectations concerning nitrosamine impurities. Where required, the assessment can incorporate structure-based scientific evaluation and computational toxicology/QSAR assessment.
Drug Logix combines pharmaceutical process understanding, impurity assessment expertise, scientific evaluation and regulatory-oriented documentation. Our objective is not only to identify potential risks, but to provide a clear scientific rationale, appropriate risk characterisation and a practical control strategy that manufacturers can actually implement and use to support regulatory and customer requirements.
Scientifically Robust | Risk-Based | Regulatory-Focused | Confidential | Client-Specific